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Background: Optimal myocardial reperfusion in ST-elevation myocardial infarction
(STEMI) is associated with lower mortality. Myocardial blush grade (MBG) quantifies
extent of reperfusion but has not been extensively correlated with infarct size measured by
MRI.
Methods: The INFUSE-AMI trial randomized patients with anterior STEMI due to
proximal or mid LAD occlusion to intracoronary bolus abciximab delivered locally via
the ClearWay RX catheter vs. no abciximab, and to manual thrombus aspiration with the
Export catheter vs. no aspiration. The primary endpoint was core laboratory assessed MRI
infarct size (IS, % of LV mass) at 30 days. Optimal MBG was defined as grade 2 or 3
assessed at a core laboratory blinded to randomization and outcomes.
Results: There were 452 patients randomized in the study. The median age was 61y, 74%
were men and 11% had diabetes. Nearly 2/3 had proximal LAD involvement. Intracoro-
nary abciximab reduced IS (% LV mass): 15.1[6.8-22.7] vs. 17.9[10.3-25.4], P0.03.
Thrombectomy had no effect on IS. Final MBG 2/3 was achieved in 81.4%. Final TIMI
3 flow was significantly more common, and cTFC and IS at 30 days were significantly
lower in patients with final MBG 2/3 than in those with MBG 0/1 (Table). There was no
significant difference in IS (% LV) between patients with MBG 2 and MBG 3 (17.5 [9.8,
25.1] vs. 16.2[6.7, 22.3], P0.30). There was no difference in ST-segment resolution
between patients with MBG 0/1 and 2/3 (Table). Total abnormal wall motion score at 30
days was lower in the MBG 2/3 patients (6.34.8 vs. 8.24.7, P0.004) and ejection
fraction was higher (mean 50.2% vs. 46.3%, P0.003). At 30 days, death (1.7% vs. 8.3%,
P0.0008) was significantly lower in the MBG 2/3 group.
Conclusions: MBG determined immediately after primary PCI for STEMI is strongly
associated with final MRI assessed infarct size (after infarct zone remodeling and
shrinkage) and death at 30 days.
MBG 0/1 MBG 2-3 P value
Final TIMI 3 flow, % 75 95.1 0.0001
Corrected TIMI frame counts 42 [32,55] 34 [28,44] 0.0005
ST- resolution, mean, % 54.3 53.8 0.95
70%, % 47.4 53.3 0.35
30%-70%, % 33.3 29.5 0.51
30%, % 19.2 17.2 0.67
Infarct size at 30 days, % of
LV mass
19.5 [11.1,
29.2]
16.7 [7.0,
22.7]
0.002
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Background: The INFUSE-AMI trial showed a significant reduction in infarct size at 30
days after intracoronary abciximab but not after mechanical thrombectomy, despite
comparable myocardial blush grades and ST-segment resolution. Intra-procedural differ-
ences in coronary flow and thrombus removal may explain the results found.
Methods: INFUSE-AMI was a 2x2 factorial design trial in which 452 patients with
STEMI and proximal or mid left anterior descending (LAD) coronary artery occlusion
receiving bivalirudin anticoagulation were randomized to bolus intracoronary abciximab
(A) via the ClearWay RX catheter vs. no abciximab, and to manual aspiration
thrombectomy (T) with the Export catheter. TIMI flow, myocardial blush, and the
presence of visible thrombus were studied before, during and after primary PCI in the 4
treatment groups.
Results: Both T and A improved TIMI flow and blush before stenting compared to
neither intervention. Both also reduced the amount of visible thrombus before stenting
(Table). However, after stenting these parameters were no longer significantly different
among the four groups. Only T	A showed a significant reduction in infarct size, as % of
LV mass measured by MRI compared all other groups (14.7[7.1, 20.6]% vs. 17.6[8.1,
25.1]%, P0.03.
Conclusions: Both T and A are both individually effective in improving reperfusion and
removing thrombus before stenting during primary PCI. Only the combination of the 2
treatments resulted in smaller infarct size, suggesting both pharmacological and mechan-
ical thrombus modification in STEMI may be required to improve outcomes.
TA T A Neither p-value
TIMI 3 flow at
baseline
13.6% 14.4% 17.1% 12.5% 0.79
TIMI flow 3
before stent
69.2% 76.8% 50.0% 27.1% 0.0001
TIMI flow 3 after
stent
90.7% 94.6% 91.9% 88.4% 0.42
Blush grade 2/3
at baseline
13.7% 15.3% 18.0% 17.1% 0.81
Blush grade 2/3
before stent
75.0% 79.8% 61.6% 38.5% 0.0001
Blush grade 2/3
after stent
82.2% 84.7% 79.1% 79.5% 0.68
Thrombus at
baseline
86.0% 85.6% 84.7% 89.3% 0.76
Thrombus
before stent
45.4% 52.5% 59.0% 77.3% 0.0002
Thrombus after
stent
0.8% 0.9% 2.7% 0.9% 0.54
Infarct size, %LV 14.7
[7.1,
20.6]
18.6
[12.5,
23.9]
17.3
[6.3,
24.6]
17.6
[9.7,
26.0]
0.12
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